User profiles for Pilar Acedo

Pilar Acedo

Group Leader at University College London (UCL)
Verified email at ucl.ac.uk
Cited by 1104

Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy

…, L Gutiérrez, LI Cabrera, R Spada, P Acedo… - Biomaterials, 2011 - Elsevier
As radio- and chemotherapy-based cancer treatments affect both tumors and healthy tissue,
cancer immunotherapy attempts to specifically enhance the natural immune response to …

Efficient and safe internalization of magnetic iron oxide nanoparticles: two fundamental requirements for biomedical applications

…, G Salas, Y Luengo, A Lázaro, P Acedo… - … , Biology and Medicine, 2014 - Elsevier
We have performed a series of in vitro tests proposed for the reliable assessment of safety
associated with nanoparticles-cell interaction. A thorough analysis of toxicity of three different …

Multimodal use of the porphyrin TMPyP: From cancer therapy to antimicrobial applications

…, A Tabero, I Mahamed, P Acedo - Journal of Porphyrins …, 2019 - World Scientific
The cationic porphyrin meso-tetra(4- N -methylpyridyl)porphine (TMPyP) has a high yield of
singlet oxygen generation upon light activation and a strong affinity for DNA. These …

Current and novel therapeutic opportunities for systemic therapy in biliary cancer

…, M Marzioni, G Mentrasti, P Acedo… - British journal of …, 2020 - nature.com
Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies that arise in
the biliary tree within and outside the liver. Beyond surgical resection, which is beneficial for …

[HTML][HTML] The state-of-the-art of phase II/III clinical trials for targeted pancreatic cancer therapies

…, G Gaggia, A Ney, I Mahamed, P Acedo - Journal of Clinical …, 2021 - mdpi.com
Pancreatic cancer is a devastating disease with very poor prognosis. Currently, surgery
followed by adjuvant chemotherapy represents the only curative option which, unfortunately, is …

[HTML][HTML] Targeting pyruvate kinase M2 and lactate dehydrogenase a is an effective combination strategy for the treatment of pancreatic cancer

GH Mohammad, V Vassileva, P Acedo… - Cancers, 2019 - mdpi.com
Reprogrammed glucose metabolism is one of the hallmarks of cancer, and increased
expression of key glycolytic enzymes, such as pyruvate kinase M2 (PKM2) and lactate …

A new protocol in photodynamic therapy: enhanced tumour cell death by combining two different photosensitizers

…, JC Stockert, M Cañete, P Acedo - … & Photobiological Sciences, 2010 - Springer
The combined application of two photosensitisers (PSs), zinc(ii) phthalocyanine (ZnPc) and
the cationic porphyrinmeso-tetrakis(4-N-methylpyridyl)porphine (T4MPyP), on HeLa cells …

[HTML][HTML] Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells

L Jiang, N Malik, P Acedo, J Zawacka-Pankau - Cell death discovery, 2019 - nature.com
p53 is a tumor suppressor, which belongs to the p53 family of proteins. The family consists
of p53, p63 and p73 proteins, which share similar structure and function. Activation of wild-…

[HTML][HTML] Biliary Strictures and Cholangiocarcinoma–Untangling a Diagnostic Conundrum

…, A Garcia-Sampedro, G Goodchild, P Acedo… - Frontiers in …, 2021 - frontiersin.org
Cholangiocarcinoma is an uncommon and highly aggressive biliary tract malignancy with
few manifestations until late disease stages. Diagnosis is currently achieved through a …

Smart nanoparticles as advanced anti-Akt kinase delivery systems for pancreatic cancer therapy

…, A Girotti, FJ Arias, SP Pereira, P Acedo - … Applied Materials & …, 2021 - ACS Publications
Pancreatic cancer is one of the deadliest cancers partly due to late diagnosis, poor drug
delivery to the target site, and acquired resistance to therapy. Therefore, more effective …